U.S. Preventive Services Task Force Supports Informed Decision making for Prostate Cancer Screening

femme cherche femme 41 By David Sampson


elenco societa che fanno trading con le azioni binarie The U.S. Preventive Services Task Force (USPSTF) has updated its recommendations for prostate cancer screening, now recommending that men 55 to 69 who are interested in screening talk to their doctors about potential benefits and harms of screening for prostate cancer before deciding whether to undergo prostate-specific antigen (PSA)-based screening. In its previous recommendation in 2012, the USPSTF recommended against screening.

enter site We asked http://irinakirilenko.com/?deribaska=bin%C3%A4re-optionen-profi-trader&742=8f binäre optionen profi trader Otis Brawley, MD, MACP, American Cancer Society chief medical officer, for his thoughts about the revised guideline.

click Otis W. Brawley, M.D.

source url “These revised recommendations from the US Preventive Services Task Force essentially bring all experts groups, including the American Cancer Society into alignment on prostate cancer screening using PSA. For some years, the ACS has called for shared decision making that incorporates individualized risks and concerns. Every man who accepts screening still should realize that there is a chance of benefit and a chance of harm. While the ACS says men at average risk start having this discussion at age 50, the USPSTF says it should happen at 55.

“Many wonder why the pendulum is swinging back towards screening, considering USPSTF’s previous guideline said there was inadequate evidence to support prostate cancer screening. The fact is, over the past few years, the benefit-to-harm ratio of PSA screening has improved as men diagnosed with prostate cancer have accepted the notion that their cancer can be watched, and if there are signs of trouble, treated. This approach, called “active surveillance,” reduces the harms of unnecessary treatment, tipping the balance towards informed decision-making.

“The USPSTF recommendation takes into account the most recent randomized trial of prostate cancer treatment and the recent treatment recommendations of a number of professional organizations. The British study, known as ProtecT, showed that a large proportion of men with screen-detected early stage prostate cancer can be safely …read more

Source:: American Cancer Society